Search research articles
Contact Us
Filters
Showing results (211-220 of 317) with videos related to
Page
of 32
Sort By:
Cell Host & Microbe
|
October 31, 2024
Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients
Angeli D G Macandog, Carlotta Catozzi, Mariaelena Capone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 21, 2023
Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials
J M Versluis, A M Menzies, K Sikorska, et al.
Nature Medicine
|
October 15, 2013
High-throughput identification of antigen-specific TCRs by TCR gene capture
Carsten Linnemann, Bianca Heemskerk, Pia Kvistborg, et al.
The New England Journal of Medicine
|
April 17, 2018
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 9, 2020
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee
O Michielin, A van Akkooi, P Lorigan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 9, 2020
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee
U Keilholz, P A Ascierto, R Dummer, et al.
Nature Medicine
|
October 13, 2020
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
Nick van Dijk, Alberto Gil-Jimenez, Karina Silina, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 17, 2024
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial
Alexander Mm Eggermont, Michal Kicinski, Christian U Blank, et al.
Cancer Cell
|
December 24, 2021
Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance
Felicity Newell, Ines Pires da Silva, Peter A Johansson, et al.
British Journal of Cancer
|
December 23, 2022
Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study
Monique K van der Kooij, Arjen Joosse, Karijn P M Suijkerbuijk, et al.
Page
of 32
Search research articles
Search
Showing results (211-220 of 317) with videos related to
Sort By:
Page
of 32
Cell Host & Microbe
|
October 31, 2024
Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients
Angeli D G Macandog, Carlotta Catozzi, Mariaelena Capone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 21, 2023
Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials
J M Versluis, A M Menzies, K Sikorska, et al.
Nature Medicine
|
October 15, 2013
High-throughput identification of antigen-specific TCRs by TCR gene capture
Carsten Linnemann, Bianca Heemskerk, Pia Kvistborg, et al.
The New England Journal of Medicine
|
April 17, 2018
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 9, 2020
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee
O Michielin, A van Akkooi, P Lorigan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 9, 2020
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee
U Keilholz, P A Ascierto, R Dummer, et al.
Nature Medicine
|
October 13, 2020
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
Nick van Dijk, Alberto Gil-Jimenez, Karina Silina, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 17, 2024
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial
Alexander Mm Eggermont, Michal Kicinski, Christian U Blank, et al.
Cancer Cell
|
December 24, 2021
Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance
Felicity Newell, Ines Pires da Silva, Peter A Johansson, et al.
British Journal of Cancer
|
December 23, 2022
Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study
Monique K van der Kooij, Arjen Joosse, Karijn P M Suijkerbuijk, et al.
Page
of 32